KYIV, UKRAINE / ACCESSWIRE / January 25, 2024 / In a crucial effort to support Ukraine’s wounded, the R.T. Weatherman Foundation is proud to announce…
The Global Partnership for Education and the Institute for Economics & Peace have released new research providing compelling evidence of the strong relationship between education…
PALO ALTO, CA / ACCESSWIRE / January 22, 2024 / Dazz, the leader in security remediation, today announced that CRN®, a brand of The Channel…
WASHINGTON, DC / ACCESSWIRE / January 18, 2024 / In a powerful and unprecedented effort, the R.T. Weatherman Foundation has organized meetings in Washington, D.C.,…
Tokyo, Japan, Boyertown, PA, and Perth, Australia BOYERTOWN, PA / ACCESSWIRE / January 17, 2024 / Global Advanced Metals Pty Ltd (GAM), a leading producer…
BARCELONA, SPAIN / ACCESSWIRE / January 15, 2024 / APRISCO ENERGY INDUSTRIES S.L., a Spain-based company dedicated to a fair and sustainable energy transition, has joined…
TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to…
Alice will lead the organization’s IMC division made up of experts in medical strategy, medical communications, publications planning and delivery, patient engagement, and more to…
Following the first official announcement at the beginning of December last year, Hyris completed the transfer of its shares into Ulisse Biomed via a reverse…
New Strategies for a Serene Trekking Vacation Unveiled MOSHI, TANZANIA / ACCESSWIRE / January 11, 2024 / Altezza Travel, the largest operator of Mount Kilimanjaro…
PFÄFFIKON, SWITZERLAND / ACCESSWIRE / January 5, 2024 / Spiden, a pioneer in non-invasive biomarker monitoring technology, is thrilled to announce a significant scientific milestone,…
Presentations and panels take place in New York the day before Retail’s Big Show DAYTON, OH / ACCESSWIRE / January 3, 2024 / Global retail…
Introducing the “Human Layer” of blockchain technology NEW YORK, NY / ACCESSWIRE / January 3, 2024 / Kadena, the world’s only truly scalable Proof of…
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 /…
SEOUL, SOUTH KOREA / ACCESSWIRE / December 20, 2023 / HFR, Inc. (KOSDAQ 230240), a leading Private 5G solution provider, has deployed an end-to-end Private…
SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / The Government of Canada has signed a contract to purchase a fleet of MQ-9B SkyGuardian®…
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies. HEIDELBERG, GERMANY / ACCESSWIRE…
PIEŠŤANY, SLOVAKIA / ACCESSWIRE / December 15, 2023 / Embark on a digital artistic journey with an award-winning painting software; Rebelle 7 by Escape Motions…
New AI-Driven Platform to Transform Clinical Outcomes Assessment: COA-AI Software Merges AI Efficiency with Researcher Expertise TUCSON, AZ / ACCESSWIRE / December 15, 2023 /…
Gabriel Joins Cleverbridge With Over a Decade of Experience Building Successful Machine Learning-Powered Software Solutions COLOGNE, GERMANY / ACCESSWIRE / December 14, 2023 / Cleverbridge,…
Latest News
Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors.


